from molecule to therapy. science. hope.
Modulari-T designs modular synthetic immune receptors and proprietary in vivo delivery vectors — making cell therapy safer, more potent, and accessible to every patient.
Who We Are.
Modulari-T Bioscience is a Montreal-based, McGill ecosystem biotech startup rewriting the rules of cell therapy. We combine natural immune receptor biology with cutting-edge AI protein design to engineer the next generation of therapeutic tools.
Our two core platforms — MARC and MoVE — work in tandem to overcome every critical failure point in existing CAR-T approaches: exhaustion, cost, manufacturing complexity, and limited immune cell targeting.
Discover Our PlatformsMARC
Modular Actuation
Receptor Cells
A synthetic immune receptor engineered to mirror the natural architecture of the T cell receptor — eliminating tonic signaling, preventing exhaustion, and delivering superior in vivo persistence across any cell type.
MoVE
Modular Vector
Platform
Immune cell-specific vectors injected intravenously — finding, activating, and genetically reprogramming target immune cells directly inside the patient's body. No lab. No delay. Just therapy.
AI Protein
Design Engine
A proprietary computational platform that designs, predicts, and optimizes MARC variants for any therapeutic target — compressing years of wet-lab iteration into weeks of in silico engineering.
Numbers that matter.
Every milestone grounded in peer-reviewed science and real clinical biology.
Backed by evidence.
Published in JITC.
Our foundational research demonstrates measurable, peer-validated superiority of MARC over conventional CAR architectures — in the world's leading immunotherapy journal.
Read Full PublicationThe Team.
Full Profiles
from idea
to action.
Whether you're an investor, pharma partner, or academic collaborator — we want to hear from you.